Zhan Yuting, Guan Xin-Yuan, Li Yan
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China.
Department of Clinical Oncology, The University of Hong Kong, Hong Kong, China.
Transl Cancer Res. 2020 Apr;9(4):2449-2459. doi: 10.21037/tcr.2020.03.11.
Hepatocellular carcinoma (HCC) is a common cancer with high morbidity and mortality, especially in East Asia. Reliable biomarkers for HCC are indispensible given the absence of capable prediction of prognosis. Long non-coding RNAs (lncRNAs) are the most abundant products of transcription, which might serve as robust markers for diagnosis or treatment.
Multiple bioinformatics tools were utilized to screen indicative lncRNAs for HCC concurrently with the underlying mechanism of its role in tumorigenesis and development. We analyzed the genome-wide alterations and transcriptomics profiles of HCC and non-tumor samples from The Cancer Genome Atlas (TCGA). Survival analyses were also applied. Integrated bioinformatics analyses were applied to identify co-expressed genes along with chromosome loci, predictive RNA binding proteins (RBPs) and co-expressed miRNAs.
Combining copy number variations (CNVs) with expressions of lncRNAs, 20 most aberrant lncRNAs were identified. MAFA-AS1 was identified as a prognostic indicator of HCC poor overall survival (OS) and disease-free survival (DFS). Multiple bioinformatics analyses suggest that MAFA-AS1 is involved in HCC progression via interacting with SRSF1/SRSF9 and coordinating with miR210.
MAFA-AS1is a prognostic biomarker for poor OS and DFS of patients with HCC. It is involved in HCC progression.
肝细胞癌（HCC）是一种常见癌症，发病率和死亡率都很高，尤其是在东亚地区。鉴于缺乏对预后的有效预测，HCC的可靠生物标志物不可或缺。长链非编码RNA（lncRNAs）是最丰富的转录产物，可能作为诊断或治疗的有力标志物。
利用多种生物信息学工具筛选HCC的指示性lncRNAs，并分析其在肿瘤发生和发展中的潜在作用机制。我们分析了来自癌症基因组图谱（TCGA）的HCC和非肿瘤样本的全基因组改变和转录组学图谱。还进行了生存分析。应用综合生物信息学分析来鉴定共表达基因以及染色体位点、预测性RNA结合蛋白（RBPs）和共表达的miRNA。
结合拷贝数变异（CNVs）和lncRNAs的表达，鉴定出20个最异常的lncRNAs。MAFA-AS1被确定为HCC总体生存（OS）和无病生存（DFS）不良的预后指标。多项生物信息学分析表明，MAFA-AS1通过与SRSF1/SRSF9相互作用并与miR210协同作用参与HCC进展。
MAFA-AS1是HCC患者OS和DFS不良的预后生物标志物。它参与HCC进展。
